BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (15)
2023
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248
-
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Blood, Vol. 141, Núm. 2, pp. 156-167
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Seminars in Hematology
-
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
Seminars in Hematology
2021
-
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336
2019
-
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
-
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Blood, Vol. 124, Núm. 9, pp. 1404-1411
2010
-
International network of cancer genome projects
Nature, Vol. 464, Núm. 7291, pp. 993-998
2009
-
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289